Science & Research

Ketamine Can Reduce Harmful Drinking by “Rewriting” Your Memories

Maladaptive reward memories (MRMs) are involved in the development and maintenance of acquired overconsumption disorders, such as harmful alcohol and drug use. Here we demonstrate that the N-methyl D-aspartate (NMDA) antagonist ketamine is able to disrupt MRMs in hazardous drinkers when administered immediately after their retrieval.

Ketamine for Unipolar and Bipolar Depression

Due to unmet clinical needs for efficient drugs with a rapid onset of antidepressant effects, we aimed to evaluate the efficacy of single-dose ketamine in different subgroups of patients with major depression and establish whether repeated ketamine administration could be a viable strategy to maintain treatment gains.

Psychedelic Psychiatry’s Brave New World

After a legally mandated, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding exciting results.

NAD+ in Aging: What It Is & Why You Need It

Rhonda Patrick explains what NAD+, why it is so important for aging and why it declines with age. She discusses some of the popular NAD+ boosters like nicotinamide riboside and nicotinamide mononucleotide, what animal and human data says and some concluding thoughts.

NAD+ Boosters: How They Slow Aging

Rhonda Patrick explains what NAD+, why it is so important for aging and why it declines with age. She discusses some of the popular NAD+ boosters like nicotinamide riboside and nicotinamide mononucleotide, what animal and human data says and some concluding thoughts.

Ketamine Isn’t an Opioid, and it Treats Depression in a Unique Way

Ketamine has gotten a bad rap as an opioid when there’s plenty of evidence suggesting it isn’t one, Johns Hopkins experts say. They believe this reputation may hamper patients from getting necessary treatment for the kinds of depression that don’t respond to typical antidepressants.

Scroll to Top